Peer-reviewed article
Research on the safety and efficacy of telitacicept in the treatment of IgA nephropathy in children.
Ying L, Yue X, Zhi C, Jiali Z, Hejia Z et al. ·
Summary
Written by AI, not yet AICS's view · claude-haiku-4-5-20251001This study is about treating a specific kidney disease (IgA nephropathy) in children with a medical drug called telitacicept. While it involves children, it is a clinical trial of a pharmaceutical treatment rather than research on child well-being, development, protection, or participation. The focus is on medical efficacy and safety in a narrowly defined disease population, not on broader child health or welfare outcomes.
Key points
Limitations
This document is a clinical pharmacology study, not research on child well-being in the sense of the African Institute for Children Studies' scope.
Abstract
This study retrospectively evaluated telitacicept in ten pediatric IgA nephropathy patients with proteinuria (24-hour urinary protein: 23.97 ± 26.63 mg/kg). All patients received steroid therapy, and half received combined immunosuppressants. After a median follow-up of 3.75 months, eight patients achieved proteinuria remission (four complete, four partial). Steroid reduction (33.3-92%) occurred in six patients, and four discontinued steroids entirely. Key clinical outcomes included improvements in protein excretion. Adverse events were mild, including injection-site reactions (2 cases), upper respiratory infection (1 case), rash (1 case), and leukopenia (1 case), with no severe events reported. Telitacicept appears effective and safe for reducing proteinuria and steroid use in pediatric IgAN.